acne scar. scar cndition and fibrosis of skin
Conditions
Interventions
Treatment - Devices
Intervention 1: 20cc patient blood will be taken and mixed with anticoagulant in a ratio of 1:10 (anticoagulant/blood). The mixture will then be centrifuged at a speed of 2,000 rpm for 3 minutes and t
20cc patient blood will be taken and mixed with anticoagulant in a ratio of 1:10 (anticoagulant/blood). The mixture will then be centrifuged at a speed of 2,000 rpm for 3 minutes and the residue will
Intervention group:The intended procedure is to be a pass of ablative fractional co2 laser – a setting of laser power: 25, dot cycle (duration): 3, energy: 30 mj, pixel pitch: 1, and ablation depth: 6
Sponsors
Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1.Patients who have polymorphic and mixed acne scar (dominantly rolling and boxcar types ,less than %20 ice pick type and no hypertrophic or keloid type) 2.Patients who dont have other skin disease 3.Patients who have skin types 3-5 in fitzpatrick scale 4. Willingness for participation in the study and signing the consent form. Exclusion criteria:1.Known allergic reaction to components of study treatment that leads to unfinished study 2.Patient is unwilling to continue the study 3.Co-treatment with other methods 4.History of keloid formation 5.Any kind of active inflammation 6. Oral isotretinoin use within the preceding 6 months 7. Diabetes, collagen vascular disease 8. Ablative or nonablative laser skin resurfacing within the preceding 12 months, 9.Pregnancy or lactation 10.If patient doesnt follow the study .
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Atrophic scar of acne. Timepoint: Before and after the intervention. Method of measurement: Photography of scar before beginning ,1 month after first session of treatment and 4 months after second session of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical improvement of scar. Timepoint: 1 month after first session of treatment and 4 months after second session of treatment. Method of measurement: Self-assessment by the patients and visual analogue scale.;Treatment associated adverse events(erythema and edema). Timepoint: days 0, 2, 4, 6, 8, 15, and 30 after each session of treatment. Method of measurement: serial photography,inspection by dermatologist and visual analogue scale.;Patients satisfaction. Timepoint: 1 month after first session of treatment and 4 months after second session of treatment. Method of measurement: Quartile scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr shima keyvan
Skin Diseases and leishmaniasis research Center, Isfahan University of Medical Sciences, Isfahan, Ir
Outcome results
None listed